TY - JOUR
T1 - Optimal use of maraviroc in clinical practice
AU - Soriano, Vincent
AU - Geretti, Anna María
AU - Perno, Carlo Federico
AU - Fätkenheuer, Gerd
AU - Pillay, Deenan
AU - Reynes, Jacques
AU - Tambussi, Giuseppe
AU - Calvez, Vincent
AU - Alcamí, José
AU - Rockstroh, Juergen
PY - 2008
Y1 - 2008
N2 - Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry into cells. It has proven potent efficacy in treatment-experienced patients with multiple drug failure. Its favourable toxicity profile makes the drug attractive for consideration in other clinical scenarios, including patients with earlier stages of disease, cardiovascular risk and viral hepatitis coinfection. Because of its unique mechanism of action-blocking viral entry, studies in patients with primary HIV infection and in the context of preexposure and postexposure prophylaxis are particularly warranted. However, given its exclusive activity against CCR5 tropic strains, viral tropism testing is mandatory before using CCR5 antagonists in the clinic. Efforts to improve the reliability of viral tropism assessment using genotypic tests are underway, and it is likely that these tools will soon replace phenotypic assays, which are more expensive, difficult to perform and take a long time.
AB - Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry into cells. It has proven potent efficacy in treatment-experienced patients with multiple drug failure. Its favourable toxicity profile makes the drug attractive for consideration in other clinical scenarios, including patients with earlier stages of disease, cardiovascular risk and viral hepatitis coinfection. Because of its unique mechanism of action-blocking viral entry, studies in patients with primary HIV infection and in the context of preexposure and postexposure prophylaxis are particularly warranted. However, given its exclusive activity against CCR5 tropic strains, viral tropism testing is mandatory before using CCR5 antagonists in the clinic. Efforts to improve the reliability of viral tropism assessment using genotypic tests are underway, and it is likely that these tools will soon replace phenotypic assays, which are more expensive, difficult to perform and take a long time.
KW - Chemokine (C-C motif) receptor 5 antagonists
KW - HIV
KW - Maraviroc
KW - Tropism
UR - http://www.scopus.com/inward/record.url?scp=56549094744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56549094744&partnerID=8YFLogxK
U2 - 10.1097/QAD.0b013e3283136d95
DO - 10.1097/QAD.0b013e3283136d95
M3 - Article
C2 - 18981762
AN - SCOPUS:56549094744
VL - 22
SP - 2231
EP - 2240
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 17
ER -